Mikicort (Budesonide)

Budesonide is a glucocorticoid receptor agonist. After binding to intracellular receptors, it alters gene transcription, suppressing pro‑inflammatory cytokines and enhancing anti‑inflammatory proteins, which together diminish immune‑cell activity and inflammation in the rectal mucosa.

The prescribed dose of Mikicort is determined by the treating physician based on disease severity, patient response and clinical guidelines. Dosage instructions are individualized and should be followed exactly as written on the prescription label.

Safety data for rectal budesonide in pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against possible risks and discuss any concerns with the patient before prescribing Mikicort to pregnant or nursing women.

To place an order, submit an enquiry on the Mikicort product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Mikicort delivers a locally acting corticosteroid, offering rapid anti‑inflammatory effects with lower systemic exposure compared with oral steroids. Compared with mesalamine suppositories, budesonide may provide stronger potency for moderate disease, but both classes are used based on physician assessment of efficacy, safety and patient preference.

Mikicort should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

Mikicort is administered rectally, typically as an enema or suppository, according to the prescribing information. The patient should follow the instructions for insertion, positioning and timing provided by the healthcare professional to ensure optimal drug delivery.

The most serious adverse events include adrenal suppression with prolonged high‑dose use, severe infections due to immunosuppression, and systemic allergic reactions such as rash, swelling or anaphylaxis. Patients should be monitored for these signs and advised to seek immediate medical attention if they occur.

Mikicort is contraindicated in individuals with known hypersensitivity to budesonide or any excipients, those with active systemic infections, and patients for whom systemic corticosteroid therapy is contraindicated. A thorough medical history should be taken to identify any conditions that would preclude its use.